The importance of Bcl-xL in TRAIL resistance appears to be variable in different cancer types (NSCLC, pancreatic cancer, glioma) and depends on the apoptotic trigger(s) applied[93,97-100]. This evidence concerns the gene BCL2L1 and familial pancreatic carcinoma.